줄기세포 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 기술별, 치료법별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Stem Cells Market Growth & Trends:

The global stem cells market size is expected to reach USD 28.89 billion by 2030, registering a CAGR of 11.41% from 2025 to 2030, according to a new report by Grand View Research, Inc. Stem cells are cells that can differentiate into a variety of other cells, eventually forming organs or tissues. Many studies have been conducted over the years to assess the true potential of stem cells, leading to a variety of applications in the fields of genetic disease treatment, neurological disorders, oncology, and organ regeneration. The market is driven by the rising number of banks, growing focus on increasing therapeutic potential of these products, and extensive research for the development of regenerative medicines, among other factors.

The growing focus on regenerative therapies is fueling market expansion. iPSCs are becoming increasingly popular for the creation of customized cellular therapies, and opening up new possibilities in regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can aid in the treatment of placenta issues during pregnancy. The researchers devised a new method for producing induced trophoblast stem cells that can be used to generate placenta cells. The research will aid in the development of an in-vitro human placenta model and pave the way for future therapies.

Moreover, COVID-19 is acting as a catalyst for promoting the market growth. Several countries such as U.S., China, and Iran, have started conducting clinical trials using cellular therapies for treatment of COVID-19 infections. Furthermore, the use of cell therapy in the treatment of COVID-19 patients has yielded excellent results, which is fueling market expansion. In January 2020, a group of researchers in Beijing, China, tested stem cell treatment on patients to see if it was beneficial against COVID-19. The study found that administering intravenous clinical-grade MSCs to COVID-19 patients during first trial of treatment, improved their functional results and promoted enhanced recovery.

Increasing prevalence of cancer is one of the key factors contributing to the growth over the forecast period. Failure of combination therapy and chemotherapy for treatment of cancer has led to the shift in preference of physicians from such therapies to autologous and allogeneic stem cell therapy, thereby boosting the growth. Moreover, key market players and the government bodies are continuously investing in cancer research. For instance, in November 2021, California Institute for Regenerative Medicine invested USD 4 million in therapy targeting patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)

Introduction of novel technologies for the usage and adoption of cell based therapy is expected to boost the growth over the forecast period. Automation in adult stem cell & cord blood processing and storage are the key technologies expected to positively influence the market growth. For instance, various scientists are aiming for the approval of safe, and successful treatments using stem cells in a broad range of diseases. In 2021, companies such as Biotech Cellino invested USD 75 million in an effort to merge Artificial Intelligence technology for the development of automated stem cell manufacturing, that has the ability to regularizing access to cell treatments while aiming to be cost effective.

On the other hand, high cost of therapy is expected to hinder the market growth. For example, Bio informant, a stem cell research firm, reported that the cost of stem cell therapy ranges between USD 5,000 and USD 8,000 per patient, with some cases costing as much as USD 25,000 or more depending on the complexity of the procedure. Furthermore, restrictions on stem cell research activities have traditionally hampered embryonic stem cell growth, resulting in a meager share of the total market despite its advantages.

Stem Cells Market Report Highlights:

• Adult stem cells held the largest revenue share of 70.76% of the market in 2024 as these cells do not involve the destruction of embryos, which is the case in embryonic stem cells
• Regenerative medicine dominated the market in 2024 owing to increasing funding by the government for the development of regenerative medicines
• The cell acquisition segment captured the highest revenue share of 33.43% of the market in 2024. The discovery of embryonic stem cells has paved the way for the development of novel treatments for several diseases
• The allogenic therapy segment captured the largest revenue share of 59.33% in 2024 with regard to revenue generation
• The pharmaceutical and biotechnology companies segment captured the largest revenue share of 54.19% in 2024

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product Segment
  • 1.1.2. Application Segment
  • 1.1.3. Technology Segment
  • 1.1.4. Therapy Segment
  • 1.1.5. End-use Segment
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List Of Secondary Sources
• 1.8. List Of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Ongoing Developments In Regenerative Medicine
    • 3.2.1.2. Rising Funds For Accelerating Stem Cell Research
    • 3.2.1.3. Growing Demand For Stem Cell Banking
    • 3.2.1.4. Increasing Prevalence Of Genetic Disorders and Cancer
  • 3.2.2. Market Restraint And Challenges Analysis
    • 3.2.2.1. Ethical Concern Related To Stem Cell Research
    • 3.2.2.2. Lack Of A Well-Defined Regulatory Framework In Certain Applications Of Stem Cell
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Stem Cells Market: Product Movement Analysis
• 4.2. Adult Stem Cells (ASCs)
  • 4.2.1. Adult Stem Cells (ASCs) Market, 2018 - 2030 (USD Billion)
  • 4.2.2. Hematopoietic
    • 4.2.2.1. Hematopoietic Market, 2018 - 2030 (USD Billion)
  • 4.2.3. Mesenchymal
    • 4.2.3.1. Mesenchymal Market, 2018 - 2030 (USD Billion)
  • 4.2.4. Neural
    • 4.2.4.1. Neural Market, 2018 - 2030 (USD Billion)
  • 4.2.5. Epithelial/Skin
    • 4.2.5.1. Epithelial/Skin Market, 2018 - 2030 (USD Billion)
  • 4.2.6. Others
    • 4.2.6.1. Others Market, 2018 - 2030 (USD Billion)
• 4.3. Human Embryonic Stem Cells (HESCs)
  • 4.3.1. Human Embryonic Stem Cells (HESCs) Market, 2018 - 2030 (USD Billion)
• 4.4. Induced Pluripotent Stem Cells (iPSCs)
  • 4.4.1. Induced Pluripotent Stem Cells (iPSCs) Market, 2018 - 2030 (USD Billion)
• 4.5. Very Small Embryonic Like Stem Cells
  • 4.5.1. Very Small Embryonic Like Stem Cells Market, 2018 - 2030 (USD Billion)

Chapter 5. Application Business Analysis

• 5.1. Stem Cells Market: Application Movement Analysis
• 5.2. Regenerative Medicine
  • 5.2.1. Regenerative Medicine Market, 2018 - 2030 (USD Billion)
  • 5.2.2. Neurology
    • 5.2.2.1. Neurology Market, 2018 - 2030 (USD Billion)
  • 5.2.3. Orthopedics
    • 5.2.3.1. Orthopedics Market, 2018 - 2030 (USD Billion)
  • 5.2.4. Oncology
    • 5.2.4.1. Oncology Market, 2018 - 2030 (USD Billion)
  • 5.2.5. Hematology
    • 5.2.5.1. Hematology Market, 2018 - 2030 (USD Billion)
  • 5.2.6. Cardiovascular and Myocardial Infraction
    • 5.2.6.1. Cardiovascular and Myocardial Infraction Market, 2018 - 2030 (USD Billion)
  • 5.2.7. Injuries
    • 5.2.7.1. Injuries Market, 2018 - 2030 (USD Billion)
  • 5.2.8. Diabetes
    • 5.2.8.1. Diabetes Market, 2018 - 2030 (USD Billion)
  • 5.2.9. Liver Disorder
    • 5.2.9.1. Liver Disorder Market, 2018 - 2030 (USD Billion)
  • 5.2.10. Incontinence
    • 5.2.10.1. Incontinence Market, 2018 - 2030 (USD Billion)
  • 5.2.11. Others
    • 5.2.11.1. Others Market, 2018 - 2030 (USD Billion)
• 5.3. Drug Discovery and Development
  • 5.3.1. Drug Discovery and Development Market, 2018 - 2030 (USD Billion)

Chapter 6. Technology Business Analysis

• 6.1. Stem Cells Market: Technology Movement Analysis
• 6.2. Cell Acquisition
  • 6.2.1. Cell Acquisition Market, 2018 - 2030 (USD Billion)
  • 6.2.2. Bone Marrow Harvest
    • 6.2.2.1. Bone Marrow Harvest Market, 2018 - 2030 (USD Billion)
  • 6.2.3. Umbilical Blood Cord
    • 6.2.3.1. Umbilical Blood Cord Market, 2018 - 2030 (USD Billion)
  • 6.2.4. Apheresis
    • 6.2.4.1. Apheresis Market, 2018 - 2030 (USD Billion)
• 6.3. Cell Production
  • 6.3.1. Cell Production Market, 2018 - 2030 (USD Billion)
  • 6.3.2. Therapeutic Cloning
    • 6.3.2.1. Therapeutic Cloning Market, 2018 - 2030 (USD Billion)
  • 6.3.3. In-vitro Fertilization
    • 6.3.3.1. In-vitro Fertilization Market, 2018 - 2030 (USD Billion)
  • 6.3.4. Cell Culture
    • 6.3.4.1. Cell Culture Market, 2018 - 2030 (USD Billion)
  • 6.3.5. Isolation
    • 6.3.5.1. Isolation Market, 2018 - 2030 (USD Billion)
• 6.4. Cryopreservation
  • 6.4.1. Cryopreservation Market, 2018 - 2030 (USD Billion)
• 6.5. Expansion and Sub-Culture
  • 6.5.1. Expansion and Sub-Culture Market, 2018 - 2030 (USD Billion)

Chapter 7. Therapy Business Analysis

• 7.1. Stem Cells Market: Therapy Movement Analysis
• 7.2. Autologous
  • 7.2.1. Autologous Market, 2018 - 2030 (USD Billion)
• 7.3. Allogeneic
  • 7.3.1. Allogeneic Market, 2018 - 2030 (USD Billion)

Chapter 8. Application Business Analysis

• 8.1. Stem Cells Market: Application Movement Analysis
• 8.2. Infectious Diseases
  • 8.2.1. Infectious Diseases Market, 2018 - 2030 (USD Billion)
• 8.3. Immunology
  • 8.3.1. Immunology Market, 2018 - 2030 (USD Billion)
• 8.4. Oncology
  • 8.4.1. Oncology Market, 2018 - 2030 (USD Billion)
• 8.5. Stem Cells
  • 8.5.1. Stem Cells Market, 2018 - 2030 (USD Billion)
• 8.6. Neurobiology
  • 8.6.1. Neurobiology Market, 2018 - 2030 (USD Billion)
• 8.7. Others
  • 8.7.1. Other Applications Market, 2018 - 2030 (USD Billion)

Chapter 9. End Use Business Analysis

• 9.1. Stem Cells Market: End-use Movement Analysis
• 9.2. Pharmaceutical and Biotechnology Companies
  • 9.2.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Billion)
• 9.3. Hospitals & Cell Banks
  • 9.3.1. Hospitals & Cell Banks Market, 2018 - 2030 (USD Billion)
• 9.4. Academic & Research Institutes
  • 9.4.1. Academic & Research Institutes Market, 2018 - 2030 (USD Billion)

Chapter 10. Regional Business Analysis

• 10.1. Stem Cells Market Share By Region, 2025 & 2030
• 10.2. North America
  • 10.2.1. North America Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.2.2. U.S.
    • 10.2.2.1. Key Country Dynamics
    • 10.2.2.2. Target Disease Prevalence
    • 10.2.2.3. Competitive Scenario
    • 10.2.2.4. Regulatory Framework
    • 10.2.2.5. U.S. Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.2.3. Canada
    • 10.2.3.1. Key Country Dynamics
    • 10.2.3.2. Target Disease Prevalence
    • 10.2.3.3. Competitive Scenario
    • 10.2.3.4. Regulatory Framework
    • 10.2.3.5. Canada Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.2.4. Mexico
    • 10.2.4.1. Key Country Dynamics
    • 10.2.4.2. Target Disease Prevalence
    • 10.2.4.3. Competitive Scenario
    • 10.2.4.4. Regulatory Framework
    • 10.2.4.5. Mexico Stem Cells Market, 2018 - 2030 (USD Billion)
• 10.3. Europe
  • 10.3.1. Europe Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.3.2. UK
    • 10.3.2.1. Key Country Dynamics
    • 10.3.2.2. Target Disease Prevalence
    • 10.3.2.3. Competitive Scenario
    • 10.3.2.4. Regulatory Framework
    • 10.3.2.5. UK Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.3.3. Germany
    • 10.3.3.1. Key Country Dynamics
    • 10.3.3.2. Target Disease Prevalence
    • 10.3.3.3. Competitive Scenario
    • 10.3.3.4. Regulatory Framework
    • 10.3.3.5. Germany Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.3.4. France
    • 10.3.4.1. Key Country Dynamics
    • 10.3.4.2. Target Disease Prevalence
    • 10.3.4.3. Competitive Scenario
    • 10.3.4.4. Regulatory Framework
    • 10.3.4.5. France Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.3.5. Italy
    • 10.3.5.1. Key Country Dynamics
    • 10.3.5.2. Target Disease Prevalence
    • 10.3.5.3. Competitive Scenario
    • 10.3.5.4. Regulatory Framework
    • 10.3.5.5. Italy Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.3.6. Spain
    • 10.3.6.1. Key Country Dynamics
    • 10.3.6.2. Target Disease Prevalence
    • 10.3.6.3. Competitive Scenario
    • 10.3.6.4. Regulatory Framework
    • 10.3.6.5. Spain Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.3.7. Denmark
    • 10.3.7.1. Key Country Dynamics
    • 10.3.7.2. Target Disease Prevalence
    • 10.3.7.3. Competitive Scenario
    • 10.3.7.4. Regulatory Framework
    • 10.3.7.5. Denmark Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.3.8. Sweden
    • 10.3.8.1. Key Country Dynamics
    • 10.3.8.2. Target Disease Prevalence
    • 10.3.8.3. Competitive Scenario
    • 10.3.8.4. Regulatory Framework
    • 10.3.8.5. Sweden Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.3.9. Norway
    • 10.3.9.1. Key Country Dynamics
    • 10.3.9.2. Target Disease Prevalence
    • 10.3.9.3. Competitive Scenario
    • 10.3.9.4. Regulatory Framework
    • 10.3.9.5. Norway Stem Cells Market, 2018 - 2030 (USD Billion)
• 10.4. Asia Pacific
  • 10.4.1. Asia Pacific Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.4.2. Japan
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Target Disease Prevalence
    • 10.4.2.3. Competitive Scenario
    • 10.4.2.4. Regulatory Framework
    • 10.4.2.5. Japan Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.4.3. China
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Target Disease Prevalence
    • 10.4.3.3. Competitive Scenario
    • 10.4.3.4. Regulatory Framework
    • 10.4.3.5. China Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.4.4. India
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Target Disease Prevalence
    • 10.4.4.3. Competitive Scenario
    • 10.4.4.4. Regulatory Framework
    • 10.4.4.5. India Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.4.5. Australia
    • 10.4.5.1. Key Country Dynamics
    • 10.4.5.2. Target Disease Prevalence
    • 10.4.5.3. Competitive Scenario
    • 10.4.5.4. Regulatory Framework
    • 10.4.5.5. Australia Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.4.6. Thailand
    • 10.4.6.1. Key Country Dynamics
    • 10.4.6.2. Target Disease Prevalence
    • 10.4.6.3. Competitive Scenario
    • 10.4.6.4. Regulatory Framework
    • 10.4.6.5. Thailand Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.4.7. South Korea
    • 10.4.7.1. Key Country Dynamics
    • 10.4.7.2. Target Disease Prevalence
    • 10.4.7.3. Competitive Scenario
    • 10.4.7.4. Regulatory Framework
    • 10.4.7.5. South Korea Stem Cells Market, 2018 - 2030 (USD Billion)
• 10.5. Latin America
  • 10.5.1. Latin America Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.5.2. Brazil
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Target Disease Prevalence
    • 10.5.2.3. Competitive Scenario
    • 10.5.2.4. Regulatory Framework
    • 10.5.2.5. Brazil Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.5.3. Argentina
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Target Disease Prevalence
    • 10.5.3.3. Competitive Scenario
    • 10.5.3.4. Regulatory Framework
    • 10.5.3.5. Argentina Stem Cells Market, 2018 - 2030 (USD Billion)
• 10.6. MEA
  • 10.6.1. MEA Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.6.2. South Africa
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Target Disease Prevalence
    • 10.6.2.3. Competitive Scenario
    • 10.6.2.4. Regulatory Framework
    • 10.6.2.5. South Africa Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.6.3. Saudi Arabia
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Target Disease Prevalence
    • 10.6.3.3. Competitive Scenario
    • 10.6.3.4. Regulatory Framework
    • 10.6.3.5. Saudi Arabia Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.6.4. UAE
    • 10.6.4.1. Key Country Dynamics
    • 10.6.4.2. Target Disease Prevalence
    • 10.6.4.3. Competitive Scenario
    • 10.6.4.4. Regulatory Framework
    • 10.6.4.5. UAE Stem Cells Market, 2018 - 2030 (USD Billion)
  • 10.6.5. Kuwait
    • 10.6.5.1. Key Country Dynamics
    • 10.6.5.2. Target Disease Prevalence
    • 10.6.5.3. Competitive Scenario
    • 10.6.5.4. Regulatory Framework
    • 10.6.5.5. Kuwait Stem Cells Market, 2018 - 2030 (USD Billion)

Chapter 11. Competitive Landscape

• 11.1. Company Categorization
• 11.2. Strategy Mapping
• 11.3. Company Market Position Analysis, 2024
• 11.4. Company Profiles/Listing
  • 11.4.1. Thermo Fisher Scientific, Inc.
    • 11.4.1.1. Overview
    • 11.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 11.4.1.3. Product Benchmarking
    • 11.4.1.4. Strategic Initiatives
  • 11.4.2. STEMCELL Technologies Inc.
    • 11.4.2.1. Overview
    • 11.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 11.4.2.3. Product Benchmarking
    • 11.4.2.4. Strategic Initiatives
  • 11.4.3. Merck KGaA
    • 11.4.3.1. Overview
    • 11.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 11.4.3.3. Product Benchmarking
    • 11.4.3.4. Strategic Initiatives
  • 11.4.4. CellGenix GmbH
    • 11.4.4.1. Overview
    • 11.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 11.4.4.3. Product Benchmarking
    • 11.4.4.4. Strategic Initiatives
  • 11.4.5. PromoCell GmbH
    • 11.4.5.1. Overview
    • 11.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 11.4.5.3. Product Benchmarking
    • 11.4.5.4. Strategic Initiatives
  • 11.4.6. Takara Holdings, Inc.
    • 11.4.6.1. Overview
    • 11.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 11.4.6.3. Product Benchmarking
    • 11.4.6.4. Strategic Initiatives
  • 11.4.7. Lonza
    • 11.4.7.1. Overview
    • 11.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 11.4.7.3. Product Benchmarking
    • 11.4.7.4. Strategic Initiatives
  • 11.4.8. Cellular Engineering Technologies
    • 11.4.8.1. Overview
    • 11.4.8.2. Product Benchmarking
    • 11.4.8.3. Strategic Initiatives
  • 11.4.9. ATCC
    • 11.4.9.1. Overview
    • 11.4.9.2. Product Benchmarking
    • 11.4.9.3. Strategic Initiatives
  • 11.4.10. AcceGen
    • 11.4.10.1. Overview
    • 11.4.10.2. Product Benchmarking
    • 11.4.10.3. Strategic Initiatives
  • 11.4.11. Cell Applications, Inc.
    • 11.4.11.1. Overview
    • 11.4.11.2. Product Benchmarking
    • 11.4.11.3. Strategic Initiatives
  • 11.4.12. Bio-Techne
    • 11.4.12.1. Overview
    • 11.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 11.4.12.3. Product Benchmarking
    • 11.4.12.4. Strategic Initiatives